NCT03262935: SYD985 vs. Physician’s Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

NCT03262935
Breast Cancer Type: HER2++
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 3
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Untreated or symptomatic brain metastases; Treatment for brain metastases within 8 weeks prior to randomization- see trial for details
https://ClinicalTrials.gov/show/NCT03262935

Comments are closed.

Up ↑